Servicio de Cardiologia

Hospital Universitario Central de Asturias

Ulcerative Colitis

Colitis

Ulcer

Breast Cancer

Mirikizumab

Trastuzumab

Lilly

Daiichi Sankyo

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Hospital Universitario Central de Asturias | Servicio de Cardiologia

Site insights

Work at this site?

Active trials

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

Trial sponsors